MedTrace Logo

Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients

NCT07209631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-10-07

No results posted yet for this study

Summary

This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.

Conditions

Interventions

OTHER

Serum Lipoprotein-a level

A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-05-01
Completion
2025-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07209631 on ClinicalTrials.gov